{'fraction_non_alphanumeric': 0.06419939577039276, 'fraction_numerical': 0.06042296072507553, 'mean_word_length': 4.81140350877193, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
CHANGES IN PLASMA l,25-(0H)2D DURING LHRH ANALOGUE TREATMENT IN GIRLS WITH CENTRAL PRECOCIOUS PUBERTY

In an attempt to better understand the control of plasma 1,25-(OH)2D concentrations during puberty, these concentrations have been measured in 12 girls (age 3 yr 6 mo-8 yr 10 mo) with central precocious puberty before and after 3, 6, 9, 12, 18 and 24 months of treatment with a LHRH analogue (Buserelin®, Hoechst). Mean and extreme values for 1,25-(OH)2D were 76 pg/ml (53-114) before treatment, 68 pg/ml (43-107) and 45 pg/ml (26-87) after 12 and 18-24 months of treatment respectively. No correlation was found at any time studied between plasma 1,25-(OH)2D and : plasma estradiol, plasma DHAS, vaginal maturation index, bone age, height gain (cm/year), plasma SmC/IGFI, serum calcium, phosphorus end alkaline phosphatase activity. Plasma 1,25(OH)2D values were also not correlated with plasma basal LH and FSH before treatment, but were significantly correlated with plasma basal LH (r = 0.67, p<0.02) and plasma basal FSH (r = 0.71, p<0.01) after 12 months of treatment.From these results, one may speculate that the control of plasma 1,25-(OH)2D during puberty is not directly dependent upon skeletal growth, skeletal maturation and ovarian secretion but could be, at least partially, dependent upon central factors.